ライフサイエンスコーパス: factor II

1 methyl-isobacteriochlorin (Ni(II) and Zn(II)-factor-II).

2 III) 2,7-dimethyl-isobacterioclorin (Co(III)-factor-II).

3 f growth factors such as insulin-like growth factor II.

4 tion factor, cleavage factor I, and cleavage factor II.

5 en ovalbumin upstream promoter transcription factor II.

6 he antiadipogenic protein COUP transcription factor II.

7 n is porcine alveolar macrophage chemotactic factor-II.

8 ther with TBP comprise general transcription factor IID.

9 on factor, IIB, in addition to transcription factor IID.

10 ranscript shortening action of transcription factor IIS.

11 olecules and TATA-binding protein-associated factor II 110.

12 chain reaction for factor V 1691A (Leiden), factor II 20 210A, methylenetetrahydrofolate reductase 6

13 active site-inhibited factor IXa (4 nM) and factor II (4 microM), factor X binds to 3-fold more plat

14 actor X/factor II site was blocked by excess factor II (4 microM).

15 ntrols the production of insulin-like growth factor II, an autocrine inducer of differentiation, thro

16 cant associations with relatively minor risk factors; (ii) analysis of multiple candidate genes in gr

17 rve 3/4-restricted genes insulin-like growth factor II and guanine deaminase protected spinal motor n

18 as been shown in vitro to insert cobalt into factor II and may have evolved to support B12 synthesis

19 proteins such as undercarboxylated forms of factor II and osteocalcin to assess tissue and functiona

20 ts are defective in insertion of cobalt into factor II and that the Salmonella CysG enzyme normally c

21 owth regulators, such as insulin-like growth factor II and the insulin-like growth factor I receptor.

22 eficient in secretion of insulin-like growth factor II and their defect can be complemented with exog

23 interactions of sex with insulin-like growth factor-II and insulin for whole-body protein synthesis.

24 warfarin monitoring method affected only by factors II and X (Fiix-prothrombin time [Fiix-PT]) compa

25 o contiguous IGF2 (human insulin-like growth factor II) and H19 genes are reciprocally imprinted in b

26 precorrin-2), ring oxidation (precorrin-2 to factor II), and iron insertion (factor II to siroheme).

27 (TATA-binding protein), TFIIS (transcription factor IIS), and a number of chromatin remodeling factor

28 CRD-BP), binds to c-myc, insulin-like growth factor II, and beta-actin mRNAs, and to H19 RNA.

29 en ovalbumin upstream promoter-transcription factor II, and the peroxisome proliferator-activated rec

30 en ovalbumin upstream promoter transcription factor II, and transcription is diminished.

31 in-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protei

32 in-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protei

33 en ovalbumin upstream promoter transcription factor II (ARP-1/COUP-TFII) and retinoid X receptor (RXR

34 The data identify insulin-like growth factor II as one developmentally important protein whose

35 ulating TAF9 deacetylation and transcription factor IID assembly.

36 The general transcription factor II B (TFIIB) plays a central role in both the ass

37 F1) and the tilapia homolog of transcription factor II B (TFIIB), that are rapidly and transiently in

38 Similarly, the recruitment of transcription factor II B and RNA polymerase II to the gamma promoter

39 in-like growth factor 1, insulin-like growth factor II, basic fibroblast growth factor, platelet-deri

40 oding the p44 subunit of basal transcription factor II (BTF2p44).

41 osphate receptor and the insulin-like growth factor II/cation-independent mannose 6-phosphate recepto

42 eceptor (CD-MPR) and the insulin-like growth factor II/cation-independent mannose 6-phosphate recepto

43 ent MPR (CD-MPR) and the insulin-like growth factor II/cation-independent MPR, carry out this process

44 r interacted directly with the transcription factor IID components hTAF(II)130 and TATA box-binding p

45 of the ring could then constrain the metallo-factor-II conformation toward that of the usual substrat

46 are stabilized by knockdown of transcription factor IIS, consistent with a requirement for RNA polyme

47 e shown that Pol II and TFIID (transcription factor IID) contact overlapping regions of the promoter,

48 ciated with the formation of a transcription factor IID-containing complex on an initiator sequence l

49 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) has been shown to inhibit myogenes

50 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) hyperactivity as a contributing fa

51 en ovalbumin upstream promoter transcription factor II (COUP-TFII) in a dose-dependent manner.

52 en Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) in Leydig cell (LC) steroidogenesi

53 en ovalbumin upstream promoter transcription factor II (COUP-TFII) in the regulation of renin gene ex

54 en Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) is an important coordinator of glu

55 en ovalbumin upstream promoter transcription factor II (COUP-TFII) is the predominant nuclear recepto

56 en ovalbumin upstream promoter-transcription factor II (COUP-TFII) promoter that binds to a factor di

57 and chicken ovalbumin upstream-transcription factor II (COUP-TFII) that promote or inhibit divergent

58 eas chicken ovalbumin upstream transcription factor II (COUP-TFII) was decreased 40% at 16 hours.

59 en ovalbumin upstream promoter-transcription factor II (COUP-TFII), a member of the nuclear receptor

60 en ovalbumin upstream promoter-transcription factor II (COUP-TFII), a member of the nuclear receptor

61 en ovalbumin upstream promoter transcription factor II (COUP-TFII).

62 en ovalbumin upstream promoter-transcription factor II (COUP-TFII).

63 en ovalbumin upstream promoter transcription factor II (COUP-TFII, also known as Nr2f2) is required f

64 Here we show that COUP transcription factor II (COUP-TFII, also known as NR2F2), a member of

65 en ovalbumin upstream promoter-transcription factor II (COUP-TFII; Nr2f2) is expressed in adipose tis

66 t of TAF proteins is shared in transcription factor II D (TFIID) and SAGA transcription regulatory co

67 factors (TAFs) that constitute transcription factor II D (TFIID) contain histone fold motifs (HFMs).

68 mals carrying a liver-specific transcription factor II D (TFIID) defect in transcription initiation.

69 Transcription factor II D (TFIID) is a multiprotein complex that nucle

70 , and the TATA binding protein transcription factor II D (TFIID) were examined in human epidermal ker

71 periments using purified PRC1, transcription factor II D (TFIID), and Mediator indicate that PRC1 blo

72 cificity protein 1, transcription initiation factor II-D, and p-RNA polymerase II, resulting in the r

73 ed that UPF3B (i) interacts with the release factors, (ii) delays translation termination and (iii) d

74 -acetyltransferase) and TFIID (Transcription factor-IID)-dependent mechanisms of transcriptional acti

75 nerve growth factor and insulin-like growth factor II, either alone or in various combinations.

76 d in combination with other non-genetic risk factors, (ii) estimation of lifetime risk trajectories,

77 ce that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells.

78 ore the hypothesis that reduced prothrombin (factor II [FII]) levels in SCD will limit vaso-occlusion

79 en ovalbumin upstream promoter transcription factor II for the DR1 sites in the proximal promoters of

80 rotein S deficiency, 0.42% (0.12%-0.53%) for factor II G202010A, 0.25% (0.12%-0.53%) for factor V G16

81 ies and genotyping of factor V Leiden (FVL), factor II G20210A (FII), and methylenetetrahydrofolate r

82 mbin, protein C, protein S, factor V G1691A, factor II G20210A) and determined the incidence of sympt

83 imprinting (LOI) of the insulin-like growth factor II gene (IGF2) in tumours.

84 omic imprinting (LOI) of insulin-like growth factor II gene (IGF2) involves abnormal activation of th

85 imprinting (LOI) of the insulin-like growth factor II gene (IGF2) is an epigenetic alteration that r

86 Human insulin-like growth factor II gene (IGF2) is overexpressed, and its imprinti

87 The insulin-like growth factor II gene (Igf2) is paternally expressed in the fet

88 alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa

89 imprinting (LOI) of the insulin-like growth factor II gene (Igf2), which shows aberrant activation o

90 14 SNPs for the MTHFR gene, the Coagulation Factor II gene and the Coagulation Factor V gene.

91 The human insulin-like growth factor II gene is regulated in a development-dependent m

92 Loss of imprinting of insulin-like growth factor-II gene (IGF2) and/or loss of heterozygosity at t

93 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to abnormal activation of

94 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2), leading to biallelic rather than

95 imprinting (LOI) of the insulin-like growth factor-II gene (IGF2).

96 We observed LOI of the insulin-like growth factor-II gene in twelve of twenty-seven informative col

97 The insulin-like growth factor-II gene lies within the 11p15.5 chromosomal locus

98 h hormone receptors, and insulin-like growth factor II genes.

99 f a soluble neuregulin isoform, glial growth factor II (GGF2), to developing rat muscles alters termi

100 erential localization of insulin-like growth factor II, guanine deaminase, peripherin, early growth r

101 The general transcription factor II H (TFIIH) is a major actor of both nucleotide

102 en associated with the general transcription factor II H (TFIIH) it activates RNA polymerase II by hy

103 anscription/DNA repair factor, transcription factor II H (TFIIH) that catalyzes the unwinding of a da

104 As a component of transcription factor II H (TFIIH), XPD is involved in DNA unwinding du

105 (NAIP); and p44, a subunit of transcription factor II H (TFIIH).

106 coding for p53, p57, and insulin-like growth factor II, have been reported in adrenal tumors.

107 dation gene and the transcription initiation factor II-I (TFII-I) are components of a novel member of

108 GTF2I-like repeats 4 and 6 of transcription factor II-I (TFII-I) exhibit modest DNA binding properti

109 e transcription factor general transcription factor II-I (TFII-I).

110 ate Mkx In particular, general transcription factor II-I repeat domain-containing protein 1 (Gtf2ird1

111 port the importance of general transcription factor II-I repeat domain-containing protein 1 (GTF2IRD1

112 omolog of human GTF2I (general transcription factor II-I), which encodes BAP-135, a target for Bruton

113 actor alpha (TNF-alpha), insulin-like growth factor II (IGF II), and parathyroid hormone-related pept

114 is strongly inhibited by insulin-like growth factor II (IGF II).

115 d carries mature 7.5-kDa insulin-like growth factor II (IGF-II) and at least 12 different high molecu

116 N-myc2 and insulin-like growth factor II (IGF-II) are coordinately overexpressed in the

117 lucagon, proinsulin, and insulin-like growth factor II (IGF-II) bind to and are degraded by IDE.

118 The insulin-like growth factor II (IGF-II) gene is located within the region of

119 The insulin-like growth factor II (IGF-II) gene is maternally imprinted in most

120 ells that do not produce insulin-like growth factor II (IGF-II) grow slowly in pure cultures but have

121 a bilateral injection of insulin-like growth factor II (IGF-II) into the dorsal hippocampus of rats o

122 Insulin-like growth factor II (IGF-II) is a major embryonic growth factor be

123 Insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) is emer

124 CRD-BP is also known as insulin-like growth factor II (IGF-II) mRNA-binding protein-1.

125 a member of a family of insulin-like growth factor II (IGF-II) mRNA-binding proteins (IMPs), is expr

126 he short-term effects of insulin-like growth factor II (IGF-II) on extraocular muscle morphometry and

127 ith both IL-3 and either insulin-like growth factor II (IGF-II) or stem cell growth factor (SCF).

128 Since insulin-like growth factor II (IGF-II) receptors facilitate the delivery of

129 ation of the polypeptide insulin-like growth factor II (IGF-II) reverses all these deficits.

130 stemic administration of insulin-like growth factor II (IGF-II), a polypeptide that crosses the blood

131 within this domain: (a) insulin-like growth factor II (IGF-II), an important autocrine growth factor

132 growth factor I (IGF-I), insulin-like growth factor II (IGF-II), and their binding proteins (IGFBPs),

133 nown PLAGL2 target gene, insulin-like growth factor II (IGF-II), was greatly diminished in the presen

134 raction of a fragment of insulin-like growth factor II (IGF-II), with the IGF-II binding site on the

135 st prevalent of which is insulin-like growth factor II (IGF-II).

136 endogenous expression of insulin-like growth factor II (IGF-II).

137 endogenous expression of insulin-like growth factor II (IGF-II).

138 ning acid hydrolases and insulin-like growth factor II (IGF-II).

139 tter also interacts with insulin-like growth factor II (IGF-II).

140 The insulin-like growth factor II (IGF-II)/mannose 6-phosphate (Man-6-P) recepto

141 IGF2R gene, encoding the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor (IGF2R),

142 n the rat, administering insulin-like growth factor II (IGF-II, also known as IGF2) significantly enh

143 nt studies indicate that insulin-like growth factor-II (IGF-II) acts as an autocrine differentiation

144 er, the up-regulation of insulin-like growth factor-II (IGF-II) expression is a predominant feature o

145 ical role of circulating insulin-like growth factor-II (IGF-II) in adult humans is poorly understood.

146 Insulin-like growth factor-II (IGF-II) is an embryonic growth promoter and c

147 ate cancer, up-regulates insulin-like growth factor-II (IGF-II) mRNA and protein levels.

148 IMP-3, a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein (IMP) family, is

149 The insulin-like growth factor-II (IGF-II) receptor (IGF2R) regulates the level

150 annose-6-phosphate (M6P)/insulin-like growth factor-II (IGF-II) receptor is a multifunctional membran

151 ium and are defective in insulin like growth factor-II (IGF-II) secretion, an autocrine/paracrine fac

152 get of let-7 regulation, insulin-like growth factor-II (IGF-II).

153 iver regeneration [ALR], insulin-like growth factor-II [IGF-II], and hepatocyte growth factor [HGF])

154 ese include the gene for insulin-like growth factor II (IGF2) and H19, which show abnormal imprint-sp

155 Extensive methylation of insulin-like growth factor II (IGF2) and hypermethylated in cancer-1 (HIC-1)

156 elic regulation of mouse insulin-like growth factor II (Igf2) as a model, we demonstrate that CTCF bi

157 Insulin-like growth factor II (IGF2) belongs to a family of growth factors t

158 Insulin-like growth factor II (IGF2) enhances memory in rodents via the mann

159 utionary analyses of the insulin-like growth factor II (IGF2) gene in teleost fishes.

160 imprinting (LOI) of the insulin-like growth factor II (IGF2) gene is associated with a predispositio

161 The insulin-like growth factor II (IGF2) gene is paternally expressed and is sur

162 eated sequences, loss of insulin-like growth factor II (IGF2) imprinting, abrogation of silencing of

163 of genomic imprinting of insulin-like growth factor II (IGF2) is a hallmark of many human neoplasms.

164 Insulin-like growth factor II (Igf2) is maternally imprinted in normal tissu

165 The gene for insulin-like growth factor II (IGF2) is normally expressed from the paternal

166 17 have higher levels of insulin-like growth factor II (IGF2) mRNA and protein in the frontal cortex

167 bryos, the expression of Insulin-like growth factor II (IGF2) plays a key role in maternal-fetal inte

168 ind and target exogenous insulin-like growth factor II (IGF2) to the prelysosomes where it is degrade

169 y true for the imprinted Insulin-like Growth Factor II (IGF2), a key regulator of embryonic growth in

170 was not linked to LOI of insulin-like growth factor II (IGF2), which was found in 2 of 10 (20%) BWS p

171 r the imprinted gene for insulin-like growth factor II (IGF2).

172 t maternal allele of the insulin-like growth factor-II (IGF2) gene, silencing of the normally active

173 nation protein 1, MYOD1; insulin-like growth factor II, IGF2; tumor suppressor candidate 33, N33; ade

174 High levels of insulin-like growth factor II (IGFII) mRNA expression are detected in many h

175 promotes translation of insulin-like growth factor II (IGFII) mRNA.

176 NAGLU and a fragment of insulin-like growth factor II (IGFII) was prepared for endocytosis by the ma

177 complexes also colocalize with transcription factor IID in these cells, further supporting a general

178 olling the expression of insulin-like growth factor-II in a kinase-independent manner.

179 en ovalbumin upstream promoter transcription factor II) in the Wolffian duct mesenchyme became inters

180 etylation/degradation of T-bet transcription factor; (ii) increases T(reg) cells, driving naive T cel

181 ave any effect on EGF or insulin-like growth factor-II-induced growth of human BACs.

182 Thus, while the host factor Ii is not essential for the formation of the M. t

183 Finally, addition of transcription factor IIS is known to cause polymerase blocked at a thy

184 Prothrombin, or coagulation factor II, is a multidomain zymogen precursor of thrombi

185 en ovalbumin upstream promoter-transcription factor II, is an orphan nuclear receptor of the steroid/

186 that restoring the normal levels of clotting factors II, IX, and X while simultaneously restoring fib

187 of TF to an electronic milieu consisting of factors II, IX, X, VII, VIIa, V, and VIIII, and the anti

188 e growth factor I and/or insulin-like growth factor II levels or secretion.

189 Factor II levels, chromogenic factor X levels, and proth

190 zing mannose 6-phosphate/insulin-like growth factor II (M-6-P/IGF-II) receptor binding to the surface

191 the mannose 6-phosphate/insulin-like growth factor-II (Man-6-P/IGF-II) receptor.

192 peptidase, receptors for insulin-like growth factor-II/Man-6-phosphate and transferrin, and a glycopr

193 The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) carries o

194 The insulin-like growth factor II/mannose 6-phosphate receptor (IGF2R) interacts

195 ) binding domains of the insulin-like growth factor II/mannose 6-phosphate receptor (Man-6-P/IGF2R),

196 A soluble form of the insulin-like growth factor II/mannose 6-phosphate receptor (sIGF-II/MPR) is

197 drate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor are predicted by

198 The insulin-like growth factor II/mannose 6-phosphate receptor is a multifunctio

199 -P) binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/MPR) have

200 The insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/MPR) is a

201 human cation-independent insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-IIR) with IG

202 e recycling pathways for insulin-like growth factor-II/mannose 6-phosphate receptor (MPR) and transfe

203 lated populations of the insulin-like growth factor-II/mannose 6-phosphate receptor, the transferrin

204 ent MPR (CD-MPR) and the insulin-like growth factor II/MPR (IGF-II/MPR), recognize a diverse populati

205 However, high levels of insulin-like growth factor II mRNA are detected in many human tumors includi

206 Vg1 RNA binding protein, Insulin-like growth factor II mRNA binding protein 1, Coding region determin

207 Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfecte

208 H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-ne

209 ophila melanogaster homologue insulin growth factor II mRNA-binding protein (IMP).

210 cardiolipin antibodies, factor VII mutation, factor II mutation, and antiphospholipid antibodies.

211 to p32, a component of the ASF/SF2 splicing factors, (ii) ORF P protein colocalizes with spliceosome

212 tes were detected in the insulin-like growth factor II P3 promoter.

213 The insulin/insulin-like growth factor (IIS) pathway comprises a single receptor, DAF-2.

214 ombin (proteins induced by vitamin K absence-factor II, PIVKA-II), and the percentage of undercarboxy

215 ming growth factor-beta, insulin-like growth factor-II, plasminogen, and urokinase-type plasminogen a

216 in-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibrobl

217 l growth factors such as insulin-like growth factor-II, platelet-derived growth factor-A, and transfo

218 which in turn decreased insulin-like growth factor II production and autocrine signaling.

219 tion of an Sp1-dependent insulin-like growth factor II promoter construct in MCF-7E cells compared wi

220 gulability, including factor V Leiden R506G, factor II (prothrombin) G20210A, and methylenetetrahydro

221 Transcription factor IIS provided roughly the same level of read-throu

222 Insulin-like growth factor II receptor (IGF2R) is a multifunctional cell sur

223 ulated the expression of insulin-like growth factor II receptor (IGF2R), which may play a part in the

224 The insulin-like growth factor II receptor (IGFIIR) gene has been identified as

225 The insulin-like growth factor II receptor (IGFIIR) has been implicated as a tum

226 dent mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-II receptor) undergoes const

227 the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosy

228 The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) forms oligomeric structur

229 the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in

230 Mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) tumor suppressor- gene mu

231 the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) with high affinity, sugge

232 the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGFIIR) as a binding protein for

233 the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF-II receptor) and its lig

234 the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF2R) is considered importa

235 the mannose 6-phosphate/insulin-like growth factor II receptor and the TGF-beta type I and II recept

236 the mannose 6-phosphate/insulin-like growth factor II receptor and the transforming growth factor be

237 dent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain required for effic

238 eat polymorphisms of the insulin-like growth factor II receptor gene (IGF2R) in oral cancer risk.

239 uences, such as BAX, the insulin-like growth factor II receptor IGFIIR, and even the mismatch repair

240 the mannose 6-phosphate/insulin-like growth factor II receptor in GUS transport across the BBB in ne

241 the mannose 6-phosphate/insulin-like growth factor II receptor, the TGF-beta type I and II receptors

242 protein-coupled receptor (GPCR) coagulation factor II receptor-like 1 (F2rl1, previously known as Pa

243 Two loci, factor II receptor-like 3 (F2RL3) and G-protein-coupled

244 the mannose 6-phosphate/insulin-like growth factor II receptor.

245 SHV of the expression of insulin-like growth factor-II receptor (IGF-IIR), a mannose-6-phosphate rece

246 The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGFIIR) plays an important role

247 face mannose 6-phosphate/insulin-like growth factor II receptors (M6P/IGF2R) bind and target exogenou

248 d to poor outcome while hepatic procoagulant factor II remained unaffected.

249 approximately 9 nM) when the shared factor X/factor II site was blocked by excess factor II (4 microM

250 to examine the effects of the transcription factor IID-specific subunit TAF130p (TAF145p) upon the T

251 xtracts, including subunits of transcription factor IID (TFIID) (yeast TAFII20 [yTAFII20], yTAFII60,

252 n, we have examined changes in transcription factor IID (TFIID) and cofactor required for Sp1 activat

253 ther TBP-containing complexes [Transcription Factor IID (TFIID) and TFIIIB] were also found to dimini

254 uced transcriptional activity, transcription factor IID (TFIID) binding is not observed.

255 r 9 (TAF9), a component in the transcription factor IID (TFIID) complex.

256 d conformational change in the transcription factor IID (TFIID) complex.

257 General transcription factor IID (TFIID) is a multisubunit protein complex inv

258 The multisubunit transcription factor IID (TFIID) is an essential component of the euka

259 Transcription factor IID (TFIID) nucleates transcription initiation co

260 Transcription factor IID (TFIID) plays a central role in regulating th

261 The general transcription factor IID (TFIID) plays a central role in the initiatio

262 Transcription factor IID (TFIID) plays a key role in regulating eukary

263 The largest transcription factor IID (TFIID) subunit, TBP-associated factor 1 (TAF

264 n5-acetyltransferase)(1,2) and transcription factor IID (TFIID)(2-4).

265 Transcription factor IID (TFIID), the TBP-containing coactivator that

266 ntial component of the general transcription factor IID (TFIID), which nucleates assembly of the prei

267 F1), causing a derepression of transcription factor IID (TFIID)-driven transcription.

268 y a parallel pathway involving transcription factor IID (TFIID).

269 iated factor (TAF) subunits of transcription factor IID (TFIID).

270 ants show reduced affinity for transcription factor IID (TFIID).

271 largest component of the basal transcription factor IID (TFIID).

272 factor 4alpha (HNF4alpha) and transcription factor IID (TFIID).

273 vator Zta recruits the general transcription factors IID (TFIID) and IIA (TFIIA) to promoter DNA and

274 imulated by the EC rescue factor stimulatory factor II (TFIIS/SII).

275 Transcription factors IIS (TFIIS) and IIF (TFIIF) are known to stimula

276 tightly associated with human transcription factor IID than hTAF(II)130 is associated with hTAF(II)2

277 lactin, osteopontin, and insulin-like growth factor-II), that can discriminate between disease-free a

278 geting of VP22 is independent of other viral factors, (ii) the carboxyl terminus of VP22 is required

279 triking and includes the insulin-like growth factor II, the cisplatin resistance-associated protein,

280 , 2.54; 23 studies, I(2) = 29%), coagulation factor II (thrombin) gene (F2) mutation G20210A (rs17999

281 e dinucleotide (CpG) site within coagulation factor II (thrombin) receptor-like 3 (F2RL3) was recentl

282 (M values) of cg03636183 in the coagulation factor II (thrombin) receptor-like 3 gene (F2RL3) (M = -

283 mbin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5 (glycoprote

284 ecorrin-2 to factor II), and iron insertion (factor II to siroheme).

285 he CREs but also by recruiting transcription factor IID to the insulin promoter via its interaction w

286 ch contains a portion of insulin-like growth factor II, to create an active, chimeric enzyme with hig

287 d stress-sensing insulin/insulin-like growth factor (IIS)/TOR signalling network, which ameliorates a

288 Autocrine gastrins, insulin-like growth factor-II, transforming growth factor-alpha, and endocri

289 nvolved in the common pathway were depleted (factor II, V, X), which corresponded to increased plasma

290 ing from 2.63 (95% CI, 1.61 to 4.29) for the factor II variant to 9.44 (95% CI, 3.34 to 26.66) for an

291 randomized to 4F-PCC (containing coagulation factors II, VII, IX, and X and proteins C and S) or plas

292 n inability to synthesize active coagulation factors II, VII, IX, and X, although there is growing ev

293 rotein, and a number of coagulation factors (factors II, VII, IX, X and proteins S and C).

294 els of fibrinogen, and increased activity of factor II, VIII, and X.

295 ced in trigeminal ganglia by neuron-specific factors, (ii) viral or virus-induced factors participate

296 esentative sequence of helix D of heparin co-factor II, was demonstrated to be potent against agronom

297 ts, revealed that oxidized Co(III) or Ni(II)-factor-II were equally good substrates, whereas Co(II)-p

298 like growth factor-I and insulin-like growth factor-II were low and remained low throughout the 7-day

299 n binds to mRNA encoding insulin-like growth factor II, which has been found to be overexpressed in H

300 equence, and is not rescued by transcription factor IIS, which is in contrast to pol II blockage by a